Bristol-Myers Squibb K.K. announced that the company has received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma (idecabtagene vicleucel), a… read more.
CAR-T cell therapy has been shown to be highly effective in treating some cancers. However, responses to this relatively new form of immunotherapy can vary, making it difficult… read more.
Mount Sinai and Memorial Sloan Kettering Cancer Center (MSK) researchers have identified therapies that can help patients with the blood cancer multiple myeloma who try an immunotherapy known… read more.
The use of tyrosine kinase inhibitors (TKIs) in the treatment of ALK-positive NSCLC is now well-established. Professor Ross Camidge (University of Colorado Cancer Centre, Denver, USA) described the lessons that… read more.
Professor Julie Vose (Nebraska, USA) updates us on the current status of BCMA CAR T-cell therapy.
Professor Sagar Lonial (Atlanta, USA) opened the UKMF by discussing the latest evidence in the management of myeloma, with comment from session chair Professor Gordon Cook (Leeds, UK).
The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.
The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.
In the video, Dr Cathy Burton (Leeds), Dr Stella Bowcock (London) and Dr Stephen Robinson (Bristol) give their highlights from this year’s BSH meeting, including the Lymphoma Specialist Interest Group (SIG) which held a… read more.
Is CAR-T cell therapy a realistic treatment option for patients with large B cell lymphoma who otherwise have no curative options or an expensive new treatment that is… read more.
Dendritic cells (DC) are known to play an important role in the initiation of primary immune responses. In cancer, deficient DCs contribute to tumour-associated immune tolerance. Functionally active… read more.
Interviewer: Esther Drain Dr Toby Eyre (Oxford), Professor Anas Younes (MSKCC, USA), Dr Andrew Davies (Southampton) and Dr Graham Collins (Oxford) discuss new data in CAR T cell therapy and the first EZH2 inhibitor, tazemetostat, in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
